1.The Clinical Significance and Characteristic Shape of Ruptured 'Very Small'Cerebral Aneurysms.
Choon Hang LEE ; Seung Kuan HONG
Journal of Korean Neurosurgical Society 1999;28(8):1115-1119
The size of unruptured intracranial aneurysms is an important factor that determines their rupture potential; however, the critical threshold size remains to be established. Some useful informations for determining the threshold size have been provided by the reports on the long-term follow-up of previously diagnosed unruptured aneurysms and clinical or autopsy studies on the size of ruptured aneurysms. Among the ninety-eight patients with ruptured cerebral aneurysms the authors managed during the last 4 years and the size of which were identified neuroradiologically and/or intraoperatively, eight cases(8.2%) had very small (maximum diameter less than 5mm) aneurysms. Their clinical features were not remarkably different from the usual aneurysmal SAH. As for the morphology, all of the eight had thin wall and narrow neck; in five cases the aneurysmsal sac had elongated shape. Several clinical reports on the ultimate rupture of previously diagnosed very small unruptured aneurysms and the formidable incidence of very small ruptured aneurysms in such clinical studies as this suggest that very small aneurysms also have a definite risk of rupture. The clinical significance of the narrow neck and elongated sac of the very small ruptured aneurysms observed in the authors' cases seems to be characteristic enough to deserve further investigation.
Aneurysm*
;
Aneurysm, Ruptured
;
Autopsy
;
Follow-Up Studies
;
Humans
;
Incidence
;
Intracranial Aneurysm
;
Neck
;
Rupture
2.Three cases of central core disease.
June Tae KO ; Dong Wook KIM ; Ki Joong KIM ; Tae Sung KO ; Yong Seung HANG ; Choon Ki LEE
Journal of the Korean Child Neurology Society 1993;1(1):186-192
No abstract available.
Myopathy, Central Core*
3.Phase II clinical trial of recombinant human granulocyte colony-stimulating factor(fhG-CSF)(KRN8601) in advanced cancer patients with myelosuppression after chemotherapy.
Jae Kyung ROH ; Jin Hyuk CHOI ; Kyung Hee LEE ; Hye Ran LEE ; Nae Choon YOO ; Joo Hang KIM ; Byung Soo KIM ; Ho Young LIM
Journal of the Korean Cancer Association 1993;25(5):725-735
No abstract available.
Drug Therapy*
;
Granulocytes*
;
Humans*
4.Therapeautic effect of hepatic arterial infusion of cisplatin in primary hepatocelluar carcinoma.
Jae Yong CHO ; Jin Hyuk CHOI ; Nae Choon YOO ; Ho Young LIM ; Joo Hang KIM ; Jae Kyung ROH ; Jong Tae LEE ; Byung Soo KIM
Journal of the Korean Cancer Association 1993;25(6):865-872
No abstract available.
Cisplatin*
5.Species Distribution and Oxacillin Resistance of Staphylococci Isolate from Blood Culture.
Do Hang KIM ; Tae Jun YOON ; Chulhun L CHANG ; Sang Jun LEE
Korean Journal of Clinical Microbiology 2001;4(1):52-57
BACKGROUND: Increase of immunocompromised patients and frequent use of indwelling catheters cause staphylococcal bacteremia, especially due to coagulase-negative staphylococci (CNS), in contrast with Staphylococcus aureus in the past. And, infections of methicillin-resistant staphylococci have been increasing in number from 1970s. In this study, species of staphylococcal isolates from blood were demonstrated, and their methicillin susceptibilities were evaluated for the empirical choice of antibiotics. METHODS: One hundred and seventy-five staphylococcal strains isolated from blood culture at Pusan National University Hospital during the year 1999 were included. Species identification, susceptibility tests by agar dilution and disk diffusion methods, and mecA gene detection by polymerase chain reaction were performed. RESULTS: S. aureus (41%), S. epidermidis (30%), S. auricuralis, S. intermedius, S. haemolyticus, S. capitis, S. simulans, S. sciuri, S. homis, and S. warneri were identified. Thirty-one stains (43.4%) of S. aureus, 43 stains (83%) of S. epidermidis, and 24 stains (46%) of other CNS are resistant to oxacllin. The results of disk diffusion test were consistant with agar dilution tests in all S. aureus strains and 95.5% of CNS strains. The results of mecA gene detection were consistant with agar dilution methods in 96.8% of S. aureus and 89.6% of CNS. CONCLUSIONS: Not only S. aureus and S. epidermidis but also other various species of staphylococci were recovered from blood, and methicillin-resistant strains reached 43.2% of S. aureus, and 64.4% of CNS. These results would help for physicians to choose primary empirical therapeutic agents of patients who are suggestive of staphylococcal bacteremia.
Agar
;
Anti-Bacterial Agents
;
Bacteremia
;
Busan
;
Catheters, Indwelling
;
Coloring Agents
;
Diffusion
;
Humans
;
Immunocompromised Host
;
Methicillin
;
Methicillin Resistance
;
Oxacillin*
;
Polymerase Chain Reaction
;
Staphylococcus
;
Staphylococcus aureus
6.Efficacy of recombinant human granulocyte colony-stimulating factor(neutrogin) for chemotherapy induced neutropenia in patients with advanced lung carcinoma.
Nae Choon YOO ; Joo Hang KIM ; Yi Young LEE ; Se Kyoo KIM ; Sung Kyoo KIM ; Won Young LEE ; Bong Soo CHA ; Jin Hyuk CHOI ; Ho Young LIM ; Jae Kyung ROH ; Byung Soo KIM
Journal of the Korean Cancer Association 1993;25(2):236-246
No abstract available.
Drug Therapy*
;
Granulocytes*
;
Humans*
;
Lung*
;
Neutropenia*
7.p53 gene mutation in hepatocellular carcinoma from Korean patients and in established hepatocellular carcinoma cell lines.
Joo Hang KIM ; Joo Bae PARK ; Mitsudomi TETSUYA ; Jung Joo CHOI ; Nae Choon YOO ; Jin Hyuk CHOI ; Ho Young LIM ; Jae Kyung ROH ; Kyung Sik LEE ; Byung Soo KIM
Journal of the Korean Cancer Association 1993;25(3):359-367
No abstract available.
Carcinoma, Hepatocellular*
;
Cell Line*
;
Genes, p53*
;
Humans
8.Effects of verapamil, tamoxifen and cyclosporin A for the modulation of multidrug resistance in human lung cancer lines.
Joo Hang KIM ; Byung Soo KIM ; Jung Joo CHOI ; Kyung Mi KIM ; Nae Choon YOO ; Jin Hyuk CHOI ; Ho Young LIM ; Jae Kyung ROH ; Kyung Sik LEE ; Byung Soo KIM
Journal of the Korean Cancer Association 1993;25(2):225-235
No abstract available.
Cyclosporine*
;
Drug Resistance, Multiple*
;
Humans*
;
Lung Neoplasms*
;
Lung*
;
Tamoxifen*
;
Verapamil*
9.Leptomeningeal Carcinomatosis in Solid Tumors; Clinical Manifestation and Treatment.
Joon Oh PARK ; Hyun Joon SHIN ; Hyung Jong KIM ; Sang Wook LEE ; Hei Cheul JEUNG ; Seung Min KIM ; Nae Choon YOO ; Hyun Cheol CHUNG ; Joo Hang KIM ; Byung Soo KIM ; Jin Sik MIN ; Jae Kyung ROH
Journal of the Korean Cancer Association 2001;33(1):34-40
PURPOSE: Leptomeningeal carcinomatosis occurs in about 5% of patients with solid tumor and is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. In general, the most commom cancers that involved the leptomeninges are breast cancer, lung cancer, and malignant melanoma. MATERIALS AND METHODS: We investigated 25 patients presented with multiple neurologic symptoms and signs who were diagnosed with leptomeningeal carcinomatosis at the Yonsei Cancer Center from January 1990 to December 1999. RESULTS: The primary disease of leptomeningeal carcinomatosis were stomach cancer (10 cases), breast cancer (7 cases), lung cancer (5 cases), unknown primary cancer (2 cases) and common bile duct cancer (1 case). All patients were presented with multiple neurologic symptoms and signs involving the central nervous system (CNS), cranial nerve or spinal nerves. Twenty-one of twenty- five patients were treated with intrathecal chemotherapy, radiotherapy, or combination therapy. Fourteen of them (66.7%) experienced improvement or stabilization of neurologic symptom and sign. The median survival was 122 days (10-2190). CONCLUSION: In conclusion, although early diagnosis and active treatment of leptomeningeal carcinomatosis may improve the quality of life in selected patients, the median survival was relatively short. Therefore, new diagnostic and therapeutic strategy for leptomeningeal carcinomatosis were needed.
Breast Neoplasms
;
Central Nervous System
;
Common Bile Duct
;
Cranial Nerves
;
Drug Therapy
;
Early Diagnosis
;
Humans
;
Lung Neoplasms
;
Melanoma
;
Meningeal Carcinomatosis*
;
Neurologic Manifestations
;
Quality of Life
;
Radiotherapy
;
Spinal Nerves
;
Stomach Neoplasms
10.P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer.
Hyun Cheol CHUNG ; Soo Jung GONG ; Nae Choon YOO ; Sung Hoon NOH ; Joo Hang KIM ; Jae Kyung ROH ; Jin Sik MIN ; Byung Soo KIM ; Kim Beom LEE
Yonsei Medical Journal 1996;37(6):397-404
The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B was composed of another twelve patients who received neoadjuvant chemotherapy plus surgery. Pre-chemotherapy p-gp was evaluated in 18 out of 24 patients (6 patients had no pre-chemotherapy paraffin blocks) and post-chemotherapy p-gp was evaluated from all 24 patients. Pre- and post-chemotherapy p-gp was expressed in 5 of 18 patients (27.8%), and 9 of 24 patients (37.5%), respectively, with immunohistochemical stain using monoclonal antibody JSB-1. No differences of disease-free survivals were observed in Group A based on post-chemotherapy p-gp expression from relapsed lesions. In Group B, there was a higher relapse rate (p = 0.04) and a lower one-year disease-free survival rate (p = 0.04) in post-chemotherapy p-gp positive patients when adjuvant treatment was done with the same regimen as neoadjuvant chemotherapy. In all patients studied, post-chemotherapy p-gp expression correlated with a higher systemic recurrence (p = 0.04). These data suggest that p-gp can be induced by an adriamycin-based chemotherapy in gastric cancer. Thus, we suggest that the prognosis of gastric cancer may be poor if a multidrug resistance (MDR)-related regimen is used in the presence of p-gp after neoadjuvant chemotherapy with an adriamycin-based regimen, even if the initial response is good.
Adult
;
Aged
;
Combined Modality Therapy
;
Dose-Response Relationship, Drug
;
Doxorubicin/administration & dosage/*therapeutic use
;
Drug Resistance
;
Female
;
Human
;
Immunohistochemistry
;
Male
;
Middle Age
;
Neoplasm Recurrence, Local
;
P-Glycoprotein/*metabolism
;
Stomach Neoplasms/*drug therapy/*metabolism/surgery
;
Survival Analysis